Montemuiño, SaraMarcos Sánchez, SorayaCalzas Rodríguez, JuliaLosada Vila, BeatrizLlorente Herrero, EstherHisado Díaz, María DoloresBusto González, Victoria ValeriTaboada, BegoñaVaquero Barrón, BlancaCouñago Lorenzo, FelipeEt al.2022-06-172022-06-172021Montemuiño Muñiz, S., Marcos Sánchez, S., Calzas Rodríguez, J., Losada Vila, B., Llorente Herrero, E., Hisado Díaz, M. D., Busto González, V. V., Taboada Valladares, B., Vaquero Barrón, B., Marcos Jiménez, F. J., Amor Alonso, S., Moradiellos, J., Rodríguez de Dios, N., & Couñago, F. (2021). Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer. Journal of Clinical and Translational Research, 7(2), 185–198. https://doi.org/10.18053/jctres.07.202102.0132382-65332424-810Xhttp://hdl.handle.net/11268/11358Background and aim: In stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors have revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC. Relevance for patients: This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.engAtribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/Neoplasias pulmonaresTerapia CombinadaQuimioterapiajournal article10.18053/jctres.07.202102.013open accessCáncerTratamiento médico